Cogent Biosciences, Inc.
COGT
$34.29
-$0.24-0.70%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 137.25% | 104.76% | 21.75% | 32.56% | 22.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.27% | 34.94% | 10.53% | 17.39% | 20.08% |
| Operating Income | -38.27% | -34.94% | -10.53% | -17.39% | -20.08% |
| Income Before Tax | -35.24% | -50.89% | -14.58% | -24.73% | -23.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.24% | -50.89% | -14.58% | -24.73% | -23.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.24% | -50.89% | -14.58% | -24.73% | -23.37% |
| EBIT | -38.27% | -34.94% | -10.53% | -17.39% | -20.08% |
| EBITDA | -38.61% | -35.23% | -10.59% | -17.48% | -20.21% |
| EPS Basic | 5.50% | -11.79% | 8.23% | -8.06% | 99.91% |
| Normalized Basic EPS | 5.49% | -11.17% | 8.22% | -8.05% | 99.91% |
| EPS Diluted | 5.50% | -11.79% | 8.23% | -8.06% | 99.91% |
| Normalized Diluted EPS | 5.49% | -11.17% | 8.22% | -8.05% | 99.91% |
| Average Basic Shares Outstanding | 43.11% | 34.97% | 24.83% | 15.42% | 139,706.04% |
| Average Diluted Shares Outstanding | 43.11% | 34.97% | 24.83% | 15.42% | 139,706.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |